Allergan will have four migraine therapies in its portfolio after licensing two oral CGRP antagonists for treatment and prevention of the debilitating headaches from Merck & Co, joining a field crowded with injectable CGRP-targeting biologics.
Allergan will have four migraine therapies in its portfolio after licensing two oral CGRP antagonists for treatment and prevention of the debilitating headaches from Merck & Co, joining a field crowded with injectable CGRP-targeting biologics.
The companies made sure to note in a 7 July joint announcement that MK-1602 and MK-8031 belong to a different...
The go-ahead to resume a trial for its only drug candidate, zetomipzomib, in hepatitis could give Kezar a glimmer of hope of reviving another halted study in lupus nephritis.
With China’s Hengrui reporting successful Phase III data for its dual GLP-1/GIP agonist, licensee Kailera is readying plans to demonstrate better efficacy than current obesity drugs.
After posting encouraging Phase II results, the company plans to meet with the US FDA about using data from an ongoing Phase III study for an accelerated approval.
Emerging Company Profile: Early-stage biotech Eolo will seek cash and deals for its novel obesity drug SANA after positive Phase I results for weight loss, lean muscle mass preservation and fat mass reduction.
Analysts see the new strategy as a way to address pressure from the Trump administration’s most favored nation drug pricing proposals.
After presenting encouraging Phase II data on the GSK-3 inhibitor elraglusib at ASCO, Actuate Therapeutics is hoping to hold a pre-NDA meeting with the US FDA.
Swiss major confident that new oncology drugs will fill revenue gap.
